Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30432
Title: | Radiotheranostics in oncology: current challenges and emerging opportunities. | Austin Authors: | Bodei, Lisa;Herrmann, Ken;Schöder, Heiko;Scott, Andrew M ;Lewis, Jason S | Affiliation: | Molecular Imaging and Therapy Olivia Newton-John Cancer Research Institute Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.. Department of Radiology, Weill Cornell Medical School, New York, NY, USA.. School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.. German Cancer Consortium, University Hospital Essen, Essen, Germany.. Department of Nuclear Medicine, University of Duisburg-Essen, University Hospital Essen, Essen, Germany.. Department of Radiology, Weill Cornell Medical School, New York, NY, USA.. Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.. |
Issue Date: | Aug-2022 | Date: | 2022-06-20 | Publication information: | Nature Reviews. Clinical Oncology 2022; 19(8): 534-550 | Abstract: | Structural imaging remains an essential component of diagnosis, staging and response assessment in patients with cancer; however, as clinicians increasingly seek to noninvasively investigate tumour phenotypes and evaluate functional and molecular responses to therapy, theranostics - the combination of diagnostic imaging with targeted therapy - is becoming more widely implemented. The field of radiotheranostics, which is the focus of this Review, combines molecular imaging (primarily PET and SPECT) with targeted radionuclide therapy, which involves the use of small molecules, peptides and/or antibodies as carriers for therapeutic radionuclides, typically those emitting α-, β- or auger-radiation. The exponential, global expansion of radiotheranostics in oncology stems from its potential to target and eliminate tumour cells with minimal adverse effects, owing to a mechanism of action that differs distinctly from that of most other systemic therapies. Currently, an enormous opportunity exists to expand the number of patients who can benefit from this technology, to address the urgent needs of many thousands of patients across the world. In this Review, we describe the clinical experience with established radiotheranostics as well as novel areas of research and various barriers to progress. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/30432 | DOI: | 10.1038/s41571-022-00652-y | ORCID: | 0000-0001-6930-7383 0000-0001-7065-4534 0000-0002-6656-295X |
Journal: | Nature reviews. Clinical oncology | PubMed URL: | 35725926 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/35725926/ | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.